Table 3.

Receipt of curative therapy according to clinical benefit group.

Patient characteristic		Adjusted odds ratio for receipt of curative therapy a
		Full sample	Low benefit b	Intermediate benefit c	High benefit d
		N=68,817	N=26,410	N=33,681	N=8726
Race	White	1.00	1.00	1.00	1.00
	Black	0.65 (0.62–0.69)	0.74 (0.67–0.81)	0.64 (0.59–0.70)	0.57 (0.48–0.68)
Agee	67–69	1.00	1.00	1.00	1.00
	70–74	0.80 (0.77–0.84)	0.79 (0.72–0.86)	0.83 (0.77–0.88)	0.86 (0.78–0.96)
	75–79	0.42 (0.40–0.44)	0.40 (0.73–0.44)	0.54 (0.50–0.58)	–
	80–84	0.15 (0.14–0.16)	0.13 (0.12–0.14)	0.20 (0.19–0.22)	–
Tumor risk f	Low	1.00	–	–	–
	Moderate	1.62 (1.57–1.68)	–	–	–
Marital status	Married	1.00	1.00	1.00	1.00
	Not married	0.68 (0.66–0.71)	0.73 (0.68–0.78)	0.68 (0.64–0.72)	0.57 (0.50–0.65)
	Unknown	0.44 (0.42–0.47)	0.48 (0.43–0.55)	0.41 (0.38–0.45)	0.45 (0.37–0.55)
Comorbidity e	0	1.00	1.00	1.00	–
	1,2	1.02 (0.99–1.06)	0.95 (0.89–1.01)	1.32 (1.25–1.40)	–
	≥3	0.67 (0.63–0.71)	0.62 (0.57–0.67)	0.84 (0.78–0.91)	–
Income	Q1: <$35,528	1.00	1.00	1.00	1.00
	Q2: $35,528–<47,930	1.28 (1.22–1.35)	1.21 (1.12–1.31)	1.34 (1.25–1.43)	1.27 (1.10–1.48)
	Q3: $47,930–<65,852	1.42 (1.35–1.50)	1.30 (1.20–1.41)	1.50 (1.39–1.61)	1.55 (1.32–1.83)
	Q4: >$65,852	1.60 (1.51–1.69)	1.37 (1.26–1.49)	1.72 (1.59–1.87)	1.98 (1.66–2.37)

^aModel adjusted for all variables in table including SEER registry and year of diagnosis. P-value<0.001 for the interaction between clinical benefit and each covariate.

^bLow-benefit: patients with low-risk tumors and life expectancy <10 years.

^cIntermediate-benefit: low-risk tumors and life expectancy ≥10 years or moderate-risk tumors and life expectancy <10 years.

^dHigh-benefit: moderate-risk tumors and life expectancy ≥10 years.

^eOdds ratios for the high benefit category not calculated for certain categories because all high-benefit patients had age <75 years and no comorbidities.

^fOdds ratios for tumor risk not calculated with benefit groups because tumor risk was used to create benefit categories.